Find a company
Biomarkers have the potential to revolutionize the diagnosis and management of psychiatric disorders which affects 1 in 5 of us during our lifetime. The present symptom based diagnoses are unreliable with more than 50% of cases misdiagnosed at first presentation leading to suboptimal, inappropriate or even dangerous treatments. We have developed SaccScan - a Point-of-Care tool which has been demonstrated to detect schizophrenia and related illnesses with better than 95% accuracy. Early economic modelling showed that early detection of schizophrenia using SaccScan could produce savings of £33,474 per patient in the case of suspected schizophrenia alone.
| Project | SaccScan eye movement test for early detection of mental illnesses |
|---|---|
| Description |
Biomarkers have the potential to revolutionize the diagnosis and management of psychiatric disorders which affects 1 in 5 of us during our lifetime. The present symptom based diagnoses are unreliable with more than 50% of cases misdiagnosed at first presentation leading to suboptimal, inappropriate or even dangerous treatments. We have developed SaccScan - a Point-of-Care tool which has been demonstrated to detect schizophrenia and related illnesses with better than 95% accuracy. Early economic modelling showed that early detection of schizophrenia using SaccScan could produce savings of £33,474 per patient in the case of suspected schizophrenia alone. |
| Funding | £ 83,333 |
| Competition | Competition 12 - General Practice of the Future |
| Competition Date | November 2016 |
| Website | http://www.saccade-diagnostics.com/landing/ |